Overview of the Efficacy of Human Papillomavirus Virus Vaccines

Seong, Jaehyun; Ryou, Sang-Mi

doi:10.4167/jbv.2020.50.3.158

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 According to a Dutch study, 15 the prevalence of vulvar cancer was stable until 2002; thereafter, the prevalence rate increased by about 5% annually between 2002 and 2010. Considering that the prevalence of HPV among young Korean women has been increasing and the introduction of HPV vaccination has been delayed compared to Denmark and the Netherlands, 16 17 18 the incidence of vulvar cancer in young Korean women was expected to increase for the time being.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea

et al. 2022

View full text Add to dashboard Cite

Background Vulvar cancer is one of the rare gynecologic malignancies. Despite the recent increasing trend of vulvar cancer in western countries due to the increased infection of human papillomavirus, there has been no study for population-based incidence of vulvar cancer in Korea. We aimed to investigate the prevalence and treatment of vulvar cancer in South Korea between 2014 and 2018. Methods Data from patients diagnosed and treated with vulvar cancer between 2014 and 2018 were obtained from the Health Insurance Review and Assessment Service/National Inpatient Sample (National In-Patient Sample) in South Korea. Results A total of 4,636,542 women were identified through the HIRA-NIS database from 2014 to 2018, of which 259 patients were diagnosed and treated for vulvar cancer. The mean age diagnosed with vulvar cancer was 62.82 (± 14.30) years in 2014, 64.19 (± 16.79) years in 2015, and 67.40 (± 14.41) years in 2016. In terms of treatment modalities, the most frequent treatment was surgery only without chemotherapy or radiation therapy. In the age-specific prevalence analysis, vulvar cancer was the most prevalent among those over 70 years old. According to multiple regression analysis, patients’ age was significantly associated with the prevalence of vulvar cancer. Vulvar cancer was more prevalent in women with low socioeconomic status (SES) compared to those with high SES in 2018 (OR, 4.242; P < 0.001). Conclusion Considering the high prevalence of vulvar cancer in the elderly, it is necessary to establish a new strategy for early screening and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea

et al. 2022

View full text Add to dashboard Cite

show abstract

“…8 In Korea, the 2-valent vaccine, which prevents HPV 16 and 18, was introduced in 2007. 18 Since 2016, when the HPV vaccine was included in the national vaccination program, 12-year-old women have been eligible for national vaccination; however, the guidelines updated in 2022 expanded the vaccination target to women aged 13-17 years. 19 Considering the timing of cervical cancer screening and HPV vaccination in Korea, cervical lesions can be effectively prevented in women up to 40 years of age; however, elderly women are vulnerable to cervical lesions.…”

Section: Resultsmentioning

confidence: 99%

“…70‐year‐old women with three consecutive negative cytology test results can discontinue screening 8 . In Korea, the 2‐valent vaccine, which prevents HPV 16 and 18, was introduced in 2007 18 . Since 2016, when the HPV vaccine was included in the national vaccination program, 12‐year‐old women have been eligible for national vaccination; however, the guidelines updated in 2022 expanded the vaccination target to women aged 13–17 years 19 .…”

Section: Discussionmentioning

confidence: 99%

The necessity of continuing cervical cancer screening of elderly Korean women aged 65 years or older

Cho

Lee

et al. 2022

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Although the incidence of cervical cancer has decreased since the 1980s in Korea, it remains high among the elderly women. This study evaluated the suitability of cervical cancer screening for elderly Korean women aged ≥65 years according to recommendations by the American Society of Cytopathology and American Society for Colposcopy and Cervical Pathology. Methods We retrospectively reviewed the records of patients who underwent cervical cancer screening, followed by liquid‐based Pap test, human papillomavirus (HPV) test, and colposcopic punch biopsy at two academic hospitals from May 2008 to May 2018. The participants were divided into two groups <65 and ≥65 years old. Logistic regression analysis was performed to evaluate the association between cytology tests, HPV tests and the occurrence of high‐risk lesions, ≥cervical intraepithelial neoplasia2 (CIN2). Results The mean patient age was 49.02 ± 15.437 (range 15–91) years. No patients aged <25 years showed atypical squamous cell‐cannot exclude high grade (ASC‐H), squamous cell carcinoma (SCC), or adenocarcinoma (ADC). The incidence of high‐grade squamous intraepithelial lesion (HISL) (39.7%) and ≥CIN 3 (40.2%) was significantly higher in patients ≥65 years of age than in other age groups. However, patients ≥65 years showed increased HSIL and HPV negativity and ASC‐H, HSIL, and HPV positivity in those with ≥CIN 2 (both p = .043). Conclusion Korean women aged ≥65 years should undergo cervical cancer screening. The relevance of HPV or Cytology test alone or co‐test for screening should be evaluated in this population.

show abstract

Human papillomavirus infection and cardiovascular mortality: a cohort study

Cheong,

Chang,

Kim

et al. 2024

European Heart Journal

View full text Add to dashboard Cite

Background and Aims High-risk human papillomavirus (HR-HPV) infection—a well-established risk factor for cervical cancer—has associations with cardiovascular disease (CVD). However, its relationship with CVD mortality remains uncertain. This study examined the associations between HR-HPV infection and CVD mortality. Methods As part of a health examination, 163 250 CVD-free Korean women (mean age: 40.2 years) underwent HR-HPV screening and were tracked for up to 17 years (median: 8.6 years). National death records identified the CVD mortality cases. Hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD mortality were estimated using Cox proportional hazard regression analyses. Results During 1 380 953 person-years of follow-up, 134 CVD deaths occurred, with a mortality rate of 9.1 per 105 person-years for HR-HPV(−) women and 14.9 per 105 person-years for HR-HPV(+) women. After adjustment for traditional CVD risk factors and confounders, the HRs (95% CI) for atherosclerotic CVD (ASCVD), ischaemic heart disease (IHD), and stroke mortality in women with HR-HPV infection compared with those without infection were 3.91 (1.85–8.26), 3.74 (1.53–9.14), and 5.86 (0.86–40.11), respectively. The association between HR-HPV infection and ASCVD mortality was stronger in women with obesity than in those without (P for interaction = .006), with corresponding HRs (95% CI) of 4.81 (1.55–14.93) for obese women and 2.86 (1.04–7.88) for non-obese women. Conclusions In this cohort study of young and middle-aged Korean women, at low risks for CVD mortality, those with HR-HPV infection had higher death rates from CVD, specifically ASCVD and IHD, with a more pronounced trend in obese individuals.

show abstract

Overview of the Efficacy of Human Papillomavirus Virus Vaccines

Cited by 4 publications

References 13 publications

Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea

Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea

The necessity of continuing cervical cancer screening of elderly Korean women aged 65 years or older

Human papillomavirus infection and cardiovascular mortality: a cohort study

Contact Info

Product

Resources

About